'If you qualify for the actual medications, that would be the best route.' Read next: Energy drinks may boost cancer growth, according to new research here's why 3 simple food rules Mary Berry swears by to stay healthy at 90 Stop falling for these 4 viral gut health trends a nutritionist explains why Nutritionist Emily English's high-protein steak bowl recipe is perfect for summer lunches Cut through the noise and get practical, expert advice, home workouts, easy nutrition and more direct to your inbox
The authors commented that in some cases, the dose had to be decreased from 20 g per day to 10 g per day, due to side effects
Most common side effects of orforglipron In phase 2 and phase 3 trials, the most frequently reported side effects were: Nausea Diarrhoea Constipation Vomiting Indigestion/dyspepsia These usually appeared during dose escalation and often settled as the body adjusted
JCI Insight 5(17):e140532 Killion EA, Wang J, Yie J, Shi SD, Bates D, Min X et al (2018) Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
For the nutritional management of type 2 diabetes
These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk
